{"schema_version":"secwatch.filing_event.v1","accession":"0001472375-25-000103","form_type":"8-K","ticker":"RGPX","cik":"0001357878","company_name":"REGENEREX PHARMA, INC.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.810230+00:00","generated_at":"2026-05-17T08:28:14.021339+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Regenerex Pharma enters exclusive collagen supply deal with Holista; minimum purchases ramp to $9M/yr","bullets":["Exclusive worldwide rights to Holista's ovine collagen for wound care; initial focus on U.S. market.","Minimum purchase commitments: $50k in 2025, $3M in 2026, $6M in 2027, $9M annually from 2028.","Regenerex to fund clinical studies and FDA regulatory approvals for advanced wound care products.","Joint collaboration on nano-collagen applications with shared IP ownership.","Agreement runs for life of patents; can be terminated on 90 days' notice or for breach/insolvency."],"urls":{"canonical":"https://secwatch.observer/filing/0001472375-25-000103","json":"https://secwatch.observer/filing/0001472375-25-000103.json","markdown":"https://secwatch.observer/filing/0001472375-25-000103.md","text":"https://secwatch.observer/filing/0001472375-25-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357878/000147237525000103/0001472375-25-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357878/000147237525000103/ixform8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:28:14.021339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}